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Abstract
Regulatory T cells (Tregs) are a specialized subpopulation of CD4
+ T cells, which act to suppress the activation of
other immune cells. Tregs represent important modulators for the interaction between lymphomas and host
microenvironment. Lymphomas are a group of serious and frequently fatal malignant diseases of lymphocytes.
Recent studies revealed that some lymphoma T cells might adopt a Treg profile. Assessment of Treg phenotypes
and genotypes in patients may offer prediction of outcome in many types of lymphomas including diffuse large B-
cell lymphoma, follicular lymphoma, cutaneous T cell lymphoma, and Hodgkin’s lymphoma. Based on characterized
roles of Tregs in lymphomas, we can categorize the various roles into four groups: (a) suppressor Tregs; (b)
malignant Tregs; (c) direct tumor-killing Tregs; and (d) incompetent Tregs. The classification into four groups is
significant in predicting prognosis and designing Tregs-based immunotherapies for treating lymphomas. In patients
with lymphomas where Tregs serve either as suppressor Tregs or malignant Tregs, anti-tumor cytotoxicity is
suppressed thus decreased numbers of Tregs are associated with a good prognosis. In contrast, in patients with
lymphomas where Tregs serve as tumor-killing Tregs and incompetent Tregs, anti-tumor cytotoxicity is enhanced
or anti-autoimmune Tregs activities are weakened thus increased numbers of Tregs are associated with a good
prognosis and reduced numbers of Tregs are associated with a poor prognosis. However, the mechanisms
underlying the various roles of Tregs in patients with lymphomas remain unknown. Therefore, further research is
needed in this regard as well as the utility of Tregs as prognostic factors and therapy strategies in different
lymphomas.
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Introduction
CD4
+CD25
highFOXP3+ Regulatory T cells (Tregs) are a
specialized subpopulation of CD4
+ T cells, which act to
suppress the activation of other immune cells, maintains
the immune system homeostasis, and suppresses effector
T cells in the periphery and control excessive response
to foreign antigens [1]. Several Treg subsets have been
identified and extensively studied. Naturally occurring
Tregs represent approximately 5% to 10% of peripheral
CD4
+ T cells in both mice and humans [2-4]. Besides
naturally occurring Tregs, there are also adaptively
induced antigen-specific Tregs. These cells exist in
markedly higher proportions within tumor-infiltrating
lymphocytes, peripheral blood lymphocytes, and/or
regional lymph node lymphocytes. It has been widely
acknowledged that tumor-related immunosuppression
plays an important role in determining both the severity
of disease and the responsiveness to therapy [5-7].
Tumor-specific Tregs require ligand-specific activation
and cell-to-cell contact to exert their suppressive activity
on tumor-specific effector T cells, which includes
decreased cytotoxity, proliferation, and type 1 T helper
cell (Th1) cytokine secretion. Through variable mechan-
isms, Tregs inhibit many adaptive and innate immune
cells, including CD4
+ T cells, CD8
+ T cells, dendritic
cells, macrophages, and B cells [8]. In recent years, it
has been shown that Tregs also inhibit NK cells in a
transforming growth factor-b (TGF-b)-dependent man-
ner [9-11]. In some tumors, high numbers of Tregs are
associated with a poor prognosis due to the fact that the
presence of Tregs in the tumor microenvironment
diminishes anti-tumor immune responses. These results
might explain why current clinical trials using cancer
peptides or dendritic cells (DCs) pulsed with antigenic
peptides induce only transient immune responses and
fail to produce therapeutic benefits [12-14].
Tregs represent important modulators for the interac-
tion between lymphomas and the host
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enhance immune protection responses elicited by
tumor-associated self-antigens. Lymphomas are a group
of serious and frequently fatal malignant diseases of
lymphocytes. Lymphomas are variable in their clinical
features. Despite significant progress, the molecular and
cellular mechanisms underlying the clinical aspects of
lymphomas are largely unknown [15]. Recent studies
revealed that some lymphoma T cells might adopt a
Treg profile as well [16]. Assessment of Treg pheno-
types and genotypes in patients may offer prediction of
outcome in many types of lymphomas including diffuse
large B-cell lymphoma (DLBCL), follicular lymphoma
(FL), cutaneous T cell lymphoma (CTCL), and Hodg-
kin’s lymphoma. Recent reports have shown that the
presence of increased numbers of activated intra-
tumoral CD4
+ T cells predicts a better overall survival
rate in patients with lymphoma [17]. But further
research is needed to clarify the complex status of Tregs
in malignant lymphomas. Based on Tregs’ roles charac-
terized in lymphomas, we can categorize various roles of
Tregs into four groups: (a) Suppressor Tregs: Tregs’
suppression of anti-tumor CD8
+ T cell-mediated
immune responses is observed in various lymphomas,
which is similar to the ones found in solid tumors, car-
cinomas, and myeloid malignancies [18]; (b) Malignant
Tregs: FOXP3 is a selective marker for a subset of adult
T cell leukemia/lymphoma (ATLL) and cutaneous T-cell
lymphomas (CTCL) suggesting that Tregs can be malig-
nant [19,20]; (c) Direct tumor-killing Tregs: Some B cell
lymphoma cells can be target cells for Tregs suppressive
cytotoxicity suggesting that Tregs are tumor cell killers
[21,22]; and (d) Incompetent Tregs: a reduced
infiltration of Tregs, which are mostly rTreg in angioim-
munoblastic T-Cell lymphoma (AITL), potentially con-
tributing to the autoimmune symptoms, suggesting that
rTregs in patients with AITL are incompetent Tregs
[23] as indicated by our new working model (Figure 1).
Our new classification of Tregs into four groups is sig-
nificant in providing an insight into the effects of Tregs-
host microenvironment interaction on Tregs’ function.
In addition, our new classification also predicts prog-
nosis of these diseases and can be very useful in design-
ing Tregs-based immunotherapies for treating
lymphomas in the future. For example, in the patients
with lymphomas where Tregs serve as either suppressor
Tregs or malignant Tregs, anti-tumor cytotoxicity is
suppressed thus decreased numbers of Tregs are asso-
ciated with a good prognosis. In contrast, patients with
lymphomas where Tregs serve as tumor-killing Tregs
and incompetent Tregs, anti-tumor cytotoxicity is
enhanced or anti-autoimmune Tregs activities are wea-
kened thus increased numbers of Tregs are associated
with a good prognosis and reduced numbers of Tregs
are associated with a poor prognosis.
Non-Hodgkin’s Lymphoma
Non-Hodgkin’s lymphoma (NHL) is a diverse group of
lymphoid malignancies, which currently remains incur-
able. NHL accounts for about 90% of lymphoid neo-
plasms. Accumulating evidence shows that Tregs are
highly concentrated in tumors, thereby fostering an
immune-privileged microenvironment. Thus, newly
diagnosed NHL patients are in an immunosuppressive
state. Peripheral blood Tregs levels are irrelevant to the
status of disease [24]. Patients with unhealthy habits
Figure 1 Figure Four types of Tregs’ functions have been identified in patients with lymphomas.
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Tregs levels. CD4
+CD25
+ FOXP3
+CD127
low Tregs are
markedly increased in peripheral blood mononuclear
cells (PBMCs) versus healthy controls regardless of lym-
phoma subtype, and correlated with disease stage and
serum lactate dehydrogenase. A high proportion of
Tregs are also present in involved tissues versus reactive
nodes. Thus, NHL cells are powerful inducers of Tregs,
which may represent a new therapeutic target [25].
FOXP3
+ Treg density is varied in different lymphoma
types and is highest in follicular lymphoma.
Lymphoma-infiltrating FOXP3
+ cells may represent
important lymphoma/host microenvironment-modula-
tors, since increased number of these cells can positively
influence survival in FL, germinal center (GC)-like
DLCBL. In a Cox regression model, considering clinical
stages and age, the numbers of FOXP3+ Tregs are of
independent prognostic significance for disease-specific
survival in GC-like DLBCL. In contrast, Tregs have a
negative prognostic effect in non-GC-like DLBCL. The
reason for these discrepancies remains unclear, although
the expression of FOXP3
+ by activated Th1 cells may
provide an explanation [19]. Lee et al indicated that an
increased percentage of FOXP3-positive Tregs in
DLBCL is predictive of better prognoses. As compared
with the others, patients with higher percentages of
FOXP3-positive Tregs on initial tumor biopsy have a
significantly longer OS (p = 0.003). When the prognostic
factors are evaluated via a multivariate model, the inter-
national prognostic index and the percentages of infil-
trating FOXP3-positive Tregs in the initial biopsy are
identified as independent predictors of OS [20].
Yang et al [26] demonstrated in NHL Tregs attenu-
ated CD8 T-cell function, thereby protecting lymphoma
cells from cytotoxic activity. Likewise, Hilchey et al [27]
demonstrated that follicular lymphoma intratumoral
Tregs suppressed CD3/CD28-costimulated autologous
and allogenic CD8
+CD25
- and CD4
+CD25
- effector T
cells. Tregs and mast cells (MCs) are involved in immu-
nosuppression in B-cell NHL and IL-9 is a key mediator
o fT r e g sa n dM C s[ 2 8 ] .T h e s em i g h tp r o v i d en o v e l
insight for the pathogenesis and possible therapeutic
strategy of B-cell NHL. T-cell hyporesponsiveness is
reversed by depleting CD25
+ cells or by adding anti-
CTLA-4, supporting the view that Tregs explain the sys-
temic immunosuppression seen in NHL. Interestingly, a
high level of soluble CD25 (sCD25) has been associated
with a poor prognosis in patients with NHL. The func-
tion and origin of this soluble receptor are not well
investigated. Tregs may release CD25 to act as a decoy
receptor for IL-2, thereby depriving T-effector cells of
growth factor IL-2 [29]. Thus, in patients of different
types of NHL, the percentage and the function of
tumor-infiltrating FOXP3+ T cells predicts different
survival. Further research is needed in the utility of
Tregs as prognostic factors and therapy strategies.
Follicular Lymphoma
Follicular lymphoma (FL) is the second most common
subtype of adult B-cell NHL in Western countries and
is characterized by the chromosome translocation t
(14;18). This abnormality promotes tumor cell survival
through overexpression of the anti-apoptotic protein
Bcl-2. Of interest, mice overexpressing Bcl-2 under the
control of the immunoglobulin enhancer develop folli-
cular hyperplasia rather than FL, indicating that patho-
genetic mechanisms other than Bcl-2 over expression
exist in FL [30]. In contrast to other B-cell lymphomas
where gene expression in the malignant B-cell popula-
tion determines survival, the composition of the lym-
phoma microenvironment at diagnosis seems to
determine the survival of patients with FL [31]. Some
studies have shown that stimulation of the T cell anti-
gen receptor (TCR) or priming with dendritic cells can
induce FOXP3 expression and the acquisition of Tregs
activity in CD4
+CD25
- T cells from normal PBMC
[32-34]. Yang et al [35] extended these findings and
demonstrated that tumor infiltrating T cells in FL-
involved lymph nodes could also be induced to express
FOXP3 through TCR stimulation. Furthermore, they
showed that CD70
+ malignant B cells could facilitate
this conversion of conventional T cells to Tregs in FL.
Ai et al found that tumor B cells alone, without artificial
TCR stimulation, could induce conventional T cells to
express FOXP3 and acquire regulatory function. In con-
trast to their malignant counterpart, normal B cells did
not induce Tregs conversion. Tregs conversion is inde-
pendent of the T cell background, as T cells isolated
from FL or normal peripheral blood are equally suscep-
tible to being converted by tumor B cells. There is a
tumor-specific mechanism by which FL tumor cells pro-
mote immune escape through the induction of Tregs
[36].
In a study where Tregs are detected in FL patients, the
median Tregs percentage at diagnosis is 10.5%. Overall,
49 patients have more than 10% Tregs, 30 have between
5% to 10%, and 19 have less than 5%, with a 5-year OS
of 80%, 74%, and 50%, respectively (p =0 . 0 0 1 ) .P a t i e n t s
with very low numbers of Tregs (< 5%) are associated
with high frequencies for refractory disease (p = 0.007).
T h ep r o g n o s t i cs i g n i f i c a n c eo fT r e g sn u m b e r si si n d e -
pendent of the FL International Prognostic Index
(FLIPI). Seven transformed diffuse large B-cell lympho-
mas (DLBCLs) have lower Tregs percentages (mean:
3.3%) than FL grades 1,2 (mean: 12.1%) or 3 (mean: 9%)
(p < 0.02). These results demonstrate that the number
of tumor-infiltrating FOXP3-positive Tregs is a predic-
tor of survival in patients with FL; high Treg numbers
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decreases during the transformation to DLBCL. Tregs
may be an important subset of cells in the tumor micro-
environment modulating the host immune response and
biologic behavior of FL [37]. In conclusion, FL tumor
cells can promote immune escape through the induction
of Tregs, whereas Tregs also can serve as direct tumor-
killing Tregs in FL.
Adult T-cell leukemia/lymphoma
Adult T-cell leukemia/lymphoma (ATLL) is an aggres-
sive lymphoma associated with human T-lymphotrophic
virus 1 (HTLV1) infection, and ATLL cells frequently
express several molecules that are characteristic of
Tregs, notably CD4, CD25, and the transcription factor
FOXP3. However, this phenotype is not characteristi-
cally found in other lymphomas [38]. Therefore it has
been recently suggested that HTLV-1 selectively infects
and transforms Tregs [39]. It is expected that HTLV-1
infected cells should be recognized and eradicated by
HTLV-1-specific cytotoxic T lymphocytes (CTLs). How-
ever, HTLV-1 specific CTLs are suppressed by Treg
activities. The reason is that HTLV-1 infected Tregs
may have a survival advantage compared to other types
of cells by suppressing host immune responses against
themselves. As a result, HTLV-1 infected CD4
+CD25
+CCR4
+ Tregs should preferentially survive, and gradu-
ally increase in numbers. Furthermore, the accumulation
of additional crucial genomic and ⁄ or epigenomic altera-
tions could cause HTLV-1 infected cells to change into
clonally proliferating ATLL cells.
Bangham et al showed that HTLV-1 induces and
maintains a high frequency of FOXP3
+ T cells by indu-
cing expression of the chemokine CCL22; the frequency
is especially high in patients with chronic ATLL. In
turn, the FOXP3
+ T cells exert both potentially benefi-
cial and harmful effects: they may suppress the growth
of autologous ATLL clones and also may suppress the
host’s cytotoxic T lymphocyte response, which normally
limits HTLV-1 replication and reduces the risk of
HTLV-1 infection-associated diseases. Although ATLL
cells may exert immune suppressive effects, ATLL is not
necessarily a tumor of classical FOXP3
+ Tregs [40].
Thus, Tregs in ATLL partly serve as malignant Tregs
and lead to progress of the disease.
Cutaneous T-Cell Lymphoma
Cutaneous T-cell lymphomas (CTCLs) are non-Hodg-
kin’s lymphomas derived from T cells that home to and
inhabit the normal function and structure of skin. There
are conflicting reports as to whether CTCLs represent a
malignancy of Tregs. Sézary syndrome (SS) is an aggres-
sive variant of cutaneous T-cell lymphoma. Heid et al.
presented convincing evidence that the malignant T
cells in a subgroup of Sézary patients are FOXP3
+
Tregs. Clonal malignant T cells show increased expres-
sion of the Treg-associated transcription factor FOXP3
and demethylation of the foxp3 gene locus, and T cells
from some of these patients suppressed T-cell prolifera-
tion in vitro [41]. Mycosis fungoides (MF) with early or
infiltrated plaques have significantly higher numbers of
FOXP3+ Tregs than CTCL unspecified or advanced MF
with tumors or transformation to large cell lymphoma.
An analysis of CTCL patients demonstrated that
increased numbers of FOXP3+ Tregs are associated
with improved survival in both MF and CTCL unspeci-
fied [42]. Knol et al. showed that functional circulating
CD4
+CD25
high FOXP3
+ regulatory T-cells in CTCL
patients are increased compared to that in healthy
donors [43]. FOXP3-positive T cells occur in higher
proportions in the dermis than in the epidermis and
probably correlate with coexisting inflammatory compo-
nents [44].
In addition to that discussed above, others have con-
trary opinions. Some studies showed that CTCL neoplas-
tic cells do not typically express a Tregs phenotype and
are associated with low numbers of FOXP3-positive
Tregs in the infiltrate. FOXP3-positive T cells are less
frequently encountered in MF than in inflammatory der-
matoses. In eight of 15 (53%) Sézary patients, significantly
reduced percentages of FOXP3
+ cells are seen in blood
(2.9%) and skin (10.4%). Interestingly, six of 15 (40%)
Sézary patients show significantly increased percentages
of FOXP3
+ cells (39.7% (blood), 20.3% (skin)); however,
these cells do not express CD25. In these latter patients,
clone-specific TCR-Vb-chain antibodies were used to
demonstrate that these FOXP3
+CD25
- cells are monoclo-
nal CTCL tumor cells. FOXP3+CD25- CTCL tumor cells
show a highly demethylated status of the Foxp3 gene
locus similar to Tregs, and they are functionally able to
suppress IL-2 mRNA induction in TCR-stimulated con-
ventional T cells. Thus, FOXP3
+CD25
- CTCL tumor
cells with functional features of Tregs define a subgroup
of Sézary patients who might carry a different prognosis
and might require different treatments [45].
In an extracorporeal photopheresis (ECP) treatment
group, the baseline of circulating CD4
+CD25
+bright per-
centages in CTCL (median: 4.3 percent) are similar to
those of healthy donors in a study. During ECP treat-
ment, CTCL patients are characterized by an early
decrease of CD4
+CD25
+bright (from 4.3 percent to 2.4
percent median after 6 months). The CD4
+CD25
+bright
decrease is associated to the disease course, as it occurs
in 91.3 percent of patients responding to treatment but
in only 25 percent of progress disease (PD) patients (p =
0.0001). ECP induces downregulation of circulating CD4
+CD25
+bright cells in CTCL is potentially associated with
response mechanisms [46].
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Tregs in certain CTCL patients, which correlates with
tumor burden. The percentages of Tregs do not differ
significantly between patients and controls. Functional
assays demonstrates a dichotomy in Tregs function: in
f o u ro u to f1 0p a t i e n t s ,C D 4
+CD25
+ T cells are incap-
able of suppressing autologous CD4
+CD25
- T-cell prolif-
eration, whereas suppressive function is intact in the
other six patients. Suppressive activity of Tregs inversely
correlates with the peripheral blood tumor burden.
Mixed lymphocyte reactions demonstrate that CD4
+CD25
- T cells from patients who lack functional Tregs
are susceptible to suppression by Tregs from healthy
controls, and have not become suppressive cells.
Furthermore, expression of FOXP3 is reduced in the
CD4
+CD25
+ Tregs of these patients compared to the
other six CTCL patients and controls [47].
Immunodeficiency develops during Sézary syndrome
(SS) progression. Krejsgaard et al. studied Tregs func-
tion and the expression of FOXP3 in SS. Eight of 15
patients stain positive with an anti-FOXP3 antibody in
malignant T cells. Western blotting analysis shows
expression of two low molecular splice forms of FOXP3,
but not of wild-type (WT) FOXP3. Malignant T cells
produce interleukin-10 and transforming growth factor-
b (TGF-b) and suppress the growth of non-malignant T
cells. The Tregs phenotype and the production of sup-
pressive cytokines are driven by aberrant activation of
Jak3 independent of the FOXP3 alternatively spliced
forms. In contrast to WT FOXP3, the low molecular
splice forms of FOXP3 have no inhibitory effect on
nuclear factor-B( N F - B) activity in reporter assays,
which is in keeping with a constitutive NF-B activity in
malignant T cells. Thus, malignant T cells express low
molecular splice forms of FOXP3 and function as Tregs.
Furthermore, FOXP3 splice forms are functionally dif-
ferent from WT FOXP3 and are not involved in the
execution of the suppressive function [48]. In conclu-
sion, the percentage and function of tumor-infiltrating
FOXP3
+ T cells predicts different survival. Tregs in
CTCLs serve as both malignant Tregs and direct tumor-
killing Tregs.
Extranodal natural killer/T-cell lymphoma
Extranodal natural killer/T-cell lymphoma (NKTCL)
usually derives from natural killer (NK) cells or, rarely,
from cytotoxic T cells. NKTCL is common in East
Asians and Mexicans, but rare in Western populations
[49]. NKTCL is often refractory to radio- or chemother-
apy and shows aggressive behaviors with poor clinical
outcomes. Therefore, risk stratification of NKTCL is
important for the appropriate management of affected
patients. However, the role of alleged risk factors of
non-Hodgkin’s lymphoma creates limitations in
evaluating the prognosis of NKTCL patients. Clinical
heterogeneity and the controversial issues on the prog-
nostic factors impose requirements for a new approach
to dealing with NKTCL.
Studies show that the percentage of FOXP3
+ subset
from PBMCs in extranodal NK/T cell lymphoma
(ENKTL) patients is significantly higher than that of
healthy individuals (p < 0.001). The FOXP3
+ subset
from PBMCs expressed CD45RO, CTLA4, GITR, CCR7,
and had an IL-10
high IFN-g+T G F - b+I L - 2
low IL-17
low
cytokine secreting phenotype. Interestingly, the existence
of EBV antigen-specific CD8
+ FOXP3
+ T r e g si sd i s c o v -
ered in ENKTL. Furthermore, the high density of
FOXP3
+ tumor infiltrated lymphocytes (TILs) is asso-
ciated with improved progression-free survival (PFS) in
ENKTL patients (p < 0.05) [50]. Kim et al. also found
that NK/T cell lymphoma (NKTCL) patients with
increased numbers of Tregs (> or = 50/0.40 mm
2)s h o w
prolonged overall and progression-free survival. In their
study, tumor-infiltrating FOXP3
+ Tregs are much rarer
in non-upper aerodigestive tract (UAT)-NKTCLs than
in UAT-NKTCLs and in patients with poor performance
status (PS), which might lead to poor clinical outcome
of patients with decreased Tregs. However, in multivari-
ate analysis, a paucity of Tregs is independently asso-
ciated with poor clinical outcome of NKTCL patients
regardless of the primary site involved and the PS.
Furthermore, the quantity of Tregs has an independent
prognostic value in analyses confined to UAT- or nasal
NKTCLs. Therefore, it is possible that Tregs might infil-
trate the NKTCL in a different manner depending on
the site involved, but still have prognostic value irre-
spective of primary tumor site. Moreover, the indepen-
dent prognostic implication of the quantity of Tregs is
consistently observed in analyses of NKTCL patients
treated with homogeneous modality. These observations
suggest that infiltration of FOXP3
+ Tregs in the tumor
microenvironment might reflect a unique and clinically
important biological aspect of NKTCL [51]. In NKTCL,
Tregs might serve as direct tumor-killing Tregs.
Peripheral T-cell Lymphoma, not otherwise
specified
Peripheral T-cell lymphomas, not otherwise specified
(PTCL-NOS), are biologically heterogeneous and have
not been successfully correlated with specific T-cell sub-
sets. Bonzheim et al. found that one PTCL-NOS case
strongly expresses FOXP3 in the neoplastic T cells and
shows unusual histomorphologic features with a dense
infiltration of the lymph node by immunoblastic T cells
and with almost no reactive background infiltrate. The
patient died shortly after diagnosis. Although the major-
ity of patients with PTCL-NOS have a poor clinical out-
come, the rapid and fatal progression seen in the
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PTCL-NOS in general. Thus, FOXP3-expression and the
associated regulatory phenotype might be an adverse
biologic and clinical factor in rare PTCL cases that con-
tributes to the aggressiveness of the tumor. All remain-
ing PTCL-NOS cases show FOXP3 positivity only in the
reactive infiltrate. FOXP3+ PTCL-NOS presumably
derived from bona fide Tregs occurs but is rare in the
Western population [52]. Like solid tumors, carcinomas,
and some type of NHL, Tregs in PTCL-NOS might
serve as suppressor Tregs and the anti-tumor cytotoxi-
city of effector T cells is suppressed in this disease.
Angioimmunoblastic T-cell Lymphoma
Angioimmunoblastic T-cell lymphoma (AITL) is one of
the nodal T-cell lymphomas and is characterized by
lymphadenopathy, B-symptoms, and an aggressive beha-
vior. Its natural history has been the subject of contro-
versy, having been considered for many years to be non-
malignant disorders or dysimmune diseases. CD4
+CD25
highFOXP3
+CD127
low Tregs in the tumor micro-
environment play an important role in lymphoma
growth regulation. Numbers of Tregs are significantly
decreased in AITL lymph nodes compared with follicu-
lar lymphoma and reactive lymph nodes. Moreover, the
few Tregs in lymph nodes of AITL are resting Tregs
(rTregs) and have a naive CD45RA
+,P D 1
-,a n dI C O S
-
phenotype, in contrast to the Tregs in follicular lympho-
mas or reactive lymph nodes [53]. This phenotype may
potentially contributes to the autoimmune symptoms, as
described in systemic lupus [54] and could participate in
the poor prognosis of AITL. Interestingly, Tregs deple-
tion is not observed in AITL peripheral blood at diagno-
sis. These data suggest that Tregs depletion could
contribute to the nodal neoplastic T (FH) expansion and
dysimmune symptoms in AITL. However, the cause of
this Tregs depletion and the mechanisms of interaction
between AITL neoplastic T-cells and Tregs remain to
be defined. PD1 is known to be expressed by the AITL
neoplastic T-cells and is also involved in the Tregs
negative regulation. It is possible that the PD1 pathway
is involved in down-regulation of the Tregs population
observed in AITL [55]. This result indicated that rTregs
in AITL are incompetent Tregs; anti-autoimmune Tregs
activities are weakened and reduced numbers of Tregs
are associated with a poor prognosis.
Anaplastic Large Cell Lymphoma
Primary cutaneous CD30+ lymphoproliferative disorders
(LPDs) are the second most common group of cuta-
neous T-cell lymphomas (CTCLs), accounting for
approximately 30% of CTCLs. This group includes pri-
mary cutaneous anaplastic large cell lymphoma (C-
ALCL), lymphomatoid papulosis (LyP), and borderline
cases. It is now generally accepted that C-ALCL and
LyP form a spectrum of disease, and that histologic cri-
teria alone are often insufficient to differentiate between
these two ends of this spectrum. FOXP3 expression in
cutaneous and systemic CD30
+ lymphoproliferations is
generally confined to tumor infiltrating Tregs. These
cells may have influence upon the clinical behavior, pos-
sibly depending upon the net degree of Tregs mediated
immune suppression of tumor cells relative to tumor
infiltrating, cytotoxic effector cells, thereby implicating
the more favorable outcome of LyP compared to C-
ALCL [56]. Only a subset of tumor cells in anaplastic
lymphoma kinase (ALK)+ ALCL expresses FOXP3, and
the level of expression varies among tumor cells, point-
ing to an intricate mechanism of FOXP3 regulation.
Recent data suggest that FOXP3 may be up-regulated as
a consequence of ALK deregulation in ALCL, as it has
been shown in ALK+ ALCL cell lines. Kasprzycka et al.
[57] demonstrated elevated FOXP3 expression in ALK+
ALCL cell lines. When transfected with nucleophosmin-
anaplastic lymphoma kinase (NPM/ALK), the lymphoid
cells can be induced to express Tregs phenotype. Inhibi-
tion of NPM/ALK function in ALK+ cell can suppress
Tregs phenotype. Furthermore, NPM/ALK induced
Tregs phenotype by activating its key effector, signal
transducers, and activators of transcription protein 3
(STAT3) to activate interleukin-10 (IL-10), transforming
growth factor b, and FOXP3 expression. These findings
identified a function for NPM/ALK as an inducer of
evasion of the immune response. Advanced research is
needed to explore the Tregs in ALCL. Tregs may serve
as the suppressor Tregs in ALCL and suppress the anti-
tumor immune response induced by effector T cells.
Hodgkin’s Lymphoma
Hodgkin’s lymphoma (HL) is characterized by the pre-
sence of a small number of tumor cells in a rich back-
ground of inflammatory cells, but the contribution of
the abundant non-tumor cells to HL pathogenesis is
poorly understood. Migratory CD4
+ cells induced by HL
cells are hyporesponsive to T-cell receptor stimulation
and suppress the activation/proliferation of the effector
CD4
+ T cells in an autologous setting. HL cells in
affected lymph nodes are surrounded by a large number
of lymphocytes expressing both CC chemokine receptor
4 (CCR4) and FOXP3 [58]. The functional role of these
TILs is still controversial. While generally considered to
represent an anti-tumor immune response, TIL in classi-
c a lH L( c H L )m i g h tr e s u l tf r o mt h ep r o f o u n d l yd e r e g u -
lated immunity of cHL patients.
Kelley et al. studied the prognostic importance of
tumor-infiltrating regulatory T lymphocytes (Tregs) and
cytotoxic T/NK lymphocytes (CTLs) in 98 diagnostic
biopsy specimens from patients with cHL. When prior
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a multivariate analysis of all clinical and biologic factors,
a FOXP3/GrB ratio of 1 or less and tumor cell expres-
sion of MAL and bcl-2 all independently predicted poor
failure-free survival (FFS) [59]. Tumor-infiltrating CTLs,
T helper 1 (Th1) cells, T helper 2 (Th2) cells, and Tregs
are detected to evaluate the prognostical significance.
The results show that in cHL, the microenvironment is
dominated by Th2 cells and Tregs; large numbers of
Th2 cells are associated with significantly improved dis-
ease-free survival (p = 0.021) and event-free survival (p
= 0.012). Furthermore, a high ratio of Tregs over Th2
cells results in a significantly shortened disease-free sur-
vival (p = 0.025). These observations suggest that Tregs
may exert inhibitory effects on anti-tumor immune
r e s p o n s e sm e d i a t e dt h r o u g hT h 2c e l l sa n dt h a tT h 2
cells may be more important for effective anti-tumor
immunity than anticipated [60]. Furthermore, an
increased number of Tregs in HL is associated with the
loss of EBV-specific immunity. Baumforth et al. found
that in EBV- infected HL cell lines, the higher levels of
Chemokine (C-C motif) ligand 20 (CCL20) in the super-
natants increase the migration of CD4
+ lymphocytes
that express FOXP3, a marker of Tregs. Inducing the
expression of CCL20 might be a mechanism by which
EBV can recruit Tregs to the microenvironment of HL
and, by doing so, prevent immune responses against the
virus-infected tumor population [61].
The malignant Hodgkin/Reed-Sternberg (HRS) cells of
classical Hodgkin lymphoma (HL) are derived from
mature B cells, but have lost a considerable part of the
B cell-specific gene expression pattern. Consequences of
such a lineage infidelity for lymphoma pathogenesis are
currently not defined. HRS cells aberrantly express the
common cytokine-receptor gamma-chain (gamma(c))
cytokine IL-21, which is usually restricted to a subset of
CD4
+ T cells, and the corresponding IL-21 receptor. IL-
21 activated STAT3 in HRS cells, up-regulates STAT3
target genes, and protects HRS cells from CD95 death
receptor-induced apoptosis. Furthermore, IL-21 is
involved in the up-regulation of CC chemokine macro-
phage-inflammatory protein-3a (MIP-3a) in HRS cells.
MIP-3a in turn attracts CCR6
+CD4
+CD25
+FOXP3
+CD127
low regulatory T cells toward HRS cells, which
might favor their immune escape. Together, these data
support the concept that aberrant expression of B line-
age-inappropriate genes plays an important role for the
biology of HL tumor cells [62]. Thus, the Tregs in HL
may serve as suppressor Tregs, and is associated with
the loss of EBV-specific immunity.
Tregs and tumor immunotherapy
Tumor-induced immunotolerance mediated by inducible
Treg (iTreg) is a major obstacle to tumor
immunotherapy. Tregs induced by a shared idiotype epi-
tope can systemically suppress T cell responses against
idiotype-derived and immunodominant foreign epitopes
in vivo. So tumor vaccines should avoid epitopes
expressed by normal cells in the draining lymph node to
achieve optimal anti-tumor efficacy [63]. In a basic
study of immunotolerance, injection of an endogenous
superantigen, i.e. the minor lymphocyte stimulatory
(Mls)-1(a), into specific TCR Vb8.1-transgenic (Tg) mice
enables generation of anergic CD25
- iTreg, the immuno-
suppressive function of which is maintained by IL-10
production via p38-mitogen-activated protein kinase
(MAPK) activation. Ovalbumin peptide OVA (323-339)
iv. injection into its specific TCR-Tg (OT-II) mice also
induces adaptive tolerance by iTreg. Peptide immu-
notherapy with p38-inhibitor after CD25
+ Treg-deple-
tion is performed in an OVA-expressing lymphoma E.
G7-bearing tolerant model establishes by adoptive trans-
fer of OT-II CD25
- iTreg, which results in suppression
of tumor growth. Similarly, the antitumor immunity
induced by peptide immunotherapy in colon carcinoma
CT26-bearing mice, in which the number of IL-10-
secreting iTreg is increased, is augmented by treatment
with p38-inhibitor after CD25
+ Treg-depletion and
results in inhibition of tumor progression. These results
suggest that simultaneous inhibition of two distinct
Treg-functions may be important to the success of
tumor immunotherapy [64]. Tregs depletion in mice
leads to tumor rejection that is dependent on T cells,
natural killer (NK) cells, and IFN-g.I nt h ea b s e n c eo f
Tregs, elevated level of IFN-g are produced by tumor-
infiltrating T cells and NK cells. Tumor rejection
observed in the absence of Tregs correlates with a sub-
stantial IFN-g-dependent increase in the numbers of
tumor-infiltrating leukocytes. The most abundant cell
populations in the tumors are macrophages. Tumor-
infiltrating macrophages from Tregs-depleted mice
express increased amounts of major histocompatibility
complex (MHC) class II, produce highly enhanced levels
of pro-inflammatory cytokines, and inhibit tumor cell
proliferation. It has been reported that tumor-infiltrating
macrophages have multi-faceted functions promoting or
counteracting tumor growth. High numbers of macro-
phages infiltrating MHC class I-deficient tumor cell line
(RMA-S) tumors in the absence of Tregs correlate with
tumor rejection suggesting that macrophages are addi-
tional targets for Tregs-mediated immune suppression
in cancer [65].
Since many types of lymphoma are Epstein Barr Virus
(EBV) positive, there are several strategies of targeting
Tregs in the immunotherapy against EBV-positive lym-
phoma [66]. (1) Manipulating Tregs functions by deplet-
ing Tregs or blocking its suppressive regulatory
molecules may provide a novel therapeutic approach for
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which can activate a Th1 response but not a regulatory
T cell type 1 (Tr1) regulatoryr e s p o n s es h o u l db ec o n -
sidered, and the concentration of peptides vaccine
should also be carefully evaluated for the vaccination
against EBV positive lymphomas. (3) Depletion of Tregs
should be performed before infusion of EBV specific
CTL to enhance the clinical therapeutic benefit of CD8
+
EBV-specific CTL immunotherapy. (4) Selection of sui-
table timepoints for infusing CTL into the patients is
important to attenuate the inhibitory effect of Tregs on
the EBV-specific CTL adoptive immunotherapy [67].
Conclusion
T h er e g u l a t o r yTc e l l s-T r e g s-p l a ya ni m p o r t a n tr o l e
in malignant lymphomas, but much remains to be clari-
fied. Differed from epithelial carcinomas, Tregs in lym-
p h o m am u s tb em o r ec o m p l e x .I np a t i e n t sw i t h
different types of lymphomas, the percentage of tumor-
infiltrating FOXP3
+ T cells predicts different survival
and prognosis. Not only the percentages but also the
functions of Tregs are critical. Our new classification of
Tregs into four groups is significant in providing an
insight into the effects of Tregs-host microenvironment
i n t e r a c t i o no nT r e g s ’ function. In addition, our new
classification also predicts prognosis of the diseases and
is very useful in designing Tregs-based immunotherapies
for treating lymphomas in the future. Therefore, it is
possible that the effect of Tregs fundamentally differs in
lymphoid malignancies compared with epithelial carci-
nomas. Further research is needed in determining how
to use Tregs as prognostic factors and therapy strategies
in treating different lymphomas.
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